Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection
Treatment with interferon-free direct-acting antivirals (DAA) has become the gold standard in chronic hepatitis C virus (HCV) infection. Nevertheless, little research about the metabolic impact of achieving sustained virological response (SVR) is available in HCV/HIV co-infected patients. This resea...
| Main Authors: | , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | English |
| Published: |
MDPI
2022
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10835/13701 |
| _version_ | 1789408409354764288 |
|---|---|
| author | Ferra-Murcia, Sergio Collado-Romacho, Antonio Ramón Nievas Soriano, Bruno José Reche Lorite, Fernando Parrón Carreño, Tesifón |
| author_facet | Ferra-Murcia, Sergio Collado-Romacho, Antonio Ramón Nievas Soriano, Bruno José Reche Lorite, Fernando Parrón Carreño, Tesifón |
| author_sort | Ferra-Murcia, Sergio |
| collection | DSpace |
| description | Treatment with interferon-free direct-acting antivirals (DAA) has become the gold standard in chronic hepatitis C virus (HCV) infection. Nevertheless, little research about the metabolic impact of achieving sustained virological response (SVR) is available in HCV/HIV co-infected patients. This research aimed to evaluate early anthropometric, lipid and liver parameters changes after achieving SVR 12 weeks after treatment (SVR12). A real-life retrospective descriptive before-after study assessed 128 DAA treatment episodes from 2015 to 2019 in HCV/HIV co-infected patients. Anthropometric parameters (weight, body mass index), lipid profile, genotype (GT) and viral load, liver data (basics laboratory necroinflammatory parameters and transient elastography (TE)) were collected before treatment with DAA (baseline), and when SVR12 was achieved. Significant increases (p < 0.01) were found in the early lipid profile, measured by LDLc (84.6 ± 35.0 vs. 108.6 ± 35.1 mg/dL) and total cholesterol (161.3 ± 41.0 vs. 183.3 ± 41.6 mg/dL). Significant changes (p < 0.05) were found in liver parameters, measured by ALT (58.2 ± 34.0 vs. 22.0 ± 16.0 U/L), bilirubin (0.8 ± 0.6 vs. 0.6 ± 0.5 mg/dL), albumin (4.2 ± 0.4 vs. 4.3 ± 0.3 g/dL) and liver stiffness (LS) (13.7 ± 13.3 vs. 11.8 ± 12.1 kPa). The main conclusions were that the use of DAA has an early negative impact on lipid metabolism. Achieving SVR12 against HCV leads to an early improvement in liver function and LS in HCV/HIV co-infected patients without interference with antiretroviral treatment (ART) and DAA. Short-term close lipid monitoring may be necessary when combining protease inhibitors. HCV-GT-3/HIV co-infected patients might require further close monitoring for residual fibrosis. These findings can be relevant for actual clinical practice. |
| format | info:eu-repo/semantics/article |
| id | oai:repositorio.ual.es:10835-13701 |
| institution | Universidad de Cuenca |
| language | English |
| publishDate | 2022 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oai:repositorio.ual.es:10835-137012023-04-12T19:20:41Z Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection Ferra-Murcia, Sergio Collado-Romacho, Antonio Ramón Nievas Soriano, Bruno José Reche Lorite, Fernando Parrón Carreño, Tesifón HCV/HIV co-infected direct-acting antivirals metabolic impact comorbidity PLWHIV before-after DAA therapy Treatment with interferon-free direct-acting antivirals (DAA) has become the gold standard in chronic hepatitis C virus (HCV) infection. Nevertheless, little research about the metabolic impact of achieving sustained virological response (SVR) is available in HCV/HIV co-infected patients. This research aimed to evaluate early anthropometric, lipid and liver parameters changes after achieving SVR 12 weeks after treatment (SVR12). A real-life retrospective descriptive before-after study assessed 128 DAA treatment episodes from 2015 to 2019 in HCV/HIV co-infected patients. Anthropometric parameters (weight, body mass index), lipid profile, genotype (GT) and viral load, liver data (basics laboratory necroinflammatory parameters and transient elastography (TE)) were collected before treatment with DAA (baseline), and when SVR12 was achieved. Significant increases (p < 0.01) were found in the early lipid profile, measured by LDLc (84.6 ± 35.0 vs. 108.6 ± 35.1 mg/dL) and total cholesterol (161.3 ± 41.0 vs. 183.3 ± 41.6 mg/dL). Significant changes (p < 0.05) were found in liver parameters, measured by ALT (58.2 ± 34.0 vs. 22.0 ± 16.0 U/L), bilirubin (0.8 ± 0.6 vs. 0.6 ± 0.5 mg/dL), albumin (4.2 ± 0.4 vs. 4.3 ± 0.3 g/dL) and liver stiffness (LS) (13.7 ± 13.3 vs. 11.8 ± 12.1 kPa). The main conclusions were that the use of DAA has an early negative impact on lipid metabolism. Achieving SVR12 against HCV leads to an early improvement in liver function and LS in HCV/HIV co-infected patients without interference with antiretroviral treatment (ART) and DAA. Short-term close lipid monitoring may be necessary when combining protease inhibitors. HCV-GT-3/HIV co-infected patients might require further close monitoring for residual fibrosis. These findings can be relevant for actual clinical practice. 2022-05-18T16:52:53Z 2022-05-18T16:52:53Z 2022-05-07 info:eu-repo/semantics/article 2077-0383 http://hdl.handle.net/10835/13701 10.3390/jcm11092639 en https://www.mdpi.com/2077-0383/11/9/2639 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess MDPI |
| spellingShingle | HCV/HIV co-infected direct-acting antivirals metabolic impact comorbidity PLWHIV before-after DAA therapy Ferra-Murcia, Sergio Collado-Romacho, Antonio Ramón Nievas Soriano, Bruno José Reche Lorite, Fernando Parrón Carreño, Tesifón Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection |
| title | Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection |
| title_full | Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection |
| title_fullStr | Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection |
| title_full_unstemmed | Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection |
| title_short | Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection |
| title_sort | real-life early anthropometric, lipid and liver changes after direct-acting antiviral therapy in plwhiv with hcv co-infection |
| topic | HCV/HIV co-infected direct-acting antivirals metabolic impact comorbidity PLWHIV before-after DAA therapy |
| url | http://hdl.handle.net/10835/13701 |
| work_keys_str_mv | AT ferramurciasergio reallifeearlyanthropometriclipidandliverchangesafterdirectactingantiviraltherapyinplwhivwithhcvcoinfection AT colladoromachoantonioramon reallifeearlyanthropometriclipidandliverchangesafterdirectactingantiviraltherapyinplwhivwithhcvcoinfection AT nievassorianobrunojose reallifeearlyanthropometriclipidandliverchangesafterdirectactingantiviraltherapyinplwhivwithhcvcoinfection AT recheloritefernando reallifeearlyanthropometriclipidandliverchangesafterdirectactingantiviraltherapyinplwhivwithhcvcoinfection AT parroncarrenotesifon reallifeearlyanthropometriclipidandliverchangesafterdirectactingantiviraltherapyinplwhivwithhcvcoinfection |